Neurology and Neurosurgery - Global Neurology Academy

Episodes 161-176 of 317

Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
NeuroFrontiers
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
- Charles Turck, PharmD, BCPS, BCCCP
- Anibal Chertcoff, MD
Examining Emerging Gut Microbiota Biomarkers for MS
Examining Emerging Gut Microbiota Biomarkers for MS
NeuroFrontiers
Examining Emerging Gut Microbiota Biomarkers for MS
New Consensus for Smoldering Disease in MS
New Consensus for Smoldering Disease in MS
NeuroFrontiers
New Consensus for Smoldering Disease in MS
MS in Children: Exploring Biomarker Research Advancements
MS in Children: Exploring Biomarker Research Advancements
NeuroFrontiers
MS in Children: Exploring Biomarker Research Advancements
- Ahmed Abdelhak, MD
Discussing Disparities in MS Care for Underrepresented Populations
Discussing Disparities in MS Care for Underrepresented Populations
NeuroFrontiers
Discussing Disparities in MS Care for Underrepresented Populations
- Charles Turck, PharmD, BCPS, BCCCP
- Tirisham Gyang, MD
- Gopika Govindan Kutty, MD
An Overview of MS Biomarkers
An Overview of MS Biomarkers
NeuroFrontiers
An Overview of MS Biomarkers
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
NeuroFrontiers
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
- Charles Turck, PharmD, BCPS, BCCCP
- Jay Avasarala, MD, PhD
Highlights from the 2023 Psych Congress
Highlights from the 2023 Psych Congress
NeuroFrontiers
Highlights from the 2023 Psych Congress
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Craig Chepke, MD, FAPA
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
NeuroFrontiers
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
Diagnosing Suspected MS: A Review of the Updated Guidelines
Diagnosing Suspected MS: A Review of the Updated Guidelines
NeuroFrontiers
Diagnosing Suspected MS: A Review of the Updated Guidelines
- Andrew Wilner, MD, FACP, FAAN
- Eoin Flanagan, MB, BCh
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
NeuroFrontiers
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
Clarity for Schizophrenia: The Latest in Drug Treatment
Clarity for Schizophrenia: The Latest in Drug Treatment
NeuroFrontiers
Clarity for Schizophrenia: The Latest in Drug Treatment
Locked Up in My Own Mind: Challenges in the Criminal Justice System
Locked Up in My Own Mind: Challenges in the Criminal Justice System
NeuroFrontiers
Locked Up in My Own Mind: Challenges in the Criminal Justice System
New Drug Approved for PPD: Solving an Unmet Need
New Drug Approved for PPD: Solving an Unmet Need
NeuroFrontiers
New Drug Approved for PPD: Solving an Unmet Need
Studying the Safety of Discontinuing DMTs in MS Older Adults
Studying the Safety of Discontinuing DMTs in MS Older Adults
NeuroFrontiers
Studying the Safety of Discontinuing DMTs in MS Older Adults
- Andrew Wilner, MD, FACP, FAAN
- John Corboy, MD, MA
Uncovering Disease Progression in Multiple Sclerosis
Uncovering Disease Progression in Multiple Sclerosis
NeuroFrontiers
Uncovering Disease Progression in Multiple Sclerosis
- Sergio Baranzini, PhD

Previous
1
2
…
9
10
11
12
13
…
19
20
Next

11/11